Guangdong Zhongsheng Pharmaceutical (SHE:002317) received marketing application approval from China's National Medical Products Administration for its brexpiprazole active pharmaceutical ingredient, according to a Saturday filing with the Shenzhen bourse.
The approval allows domestic manufacturing and marketing registration for the product, which is indicated for schizophrenia in adults.
Shares rose 2% during afternoon trading on Monday.